CoChat
Sign Up
Cited by 141Multiple Myeloma Research and TreatmentsChemokine receptors and signalingChronic Lymphocytic Leukemia Research

The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond

Open access
Ullah, Tomalika Rahmat·2019·Journal of Bone Oncology
DOI 10.1016/j.jbo.2019.100253PMC PMC6658931
Open this paper in CoChat — free accountOpen PDF

Abstract

CXCR4 is a pleiotropic chemokine receptor which acts through its ligand CXCL12 to regulate diverse physiological processes. CXCR4/CXCL12 axis plays a pivotal role in proliferation, invasion, dissemination and drug resistance in multiple myeloma (MM). Apart from its role in homing, CXCR4 also affects MM cell mobilization and egression out of the bone marrow (BM) which is correlated with distant organ metastasis. Aberrant CXCR4 expression pattern is associated with osteoclastogenesis and tumor growth in MM through its cross talk with various important cell signalling pathways. A deeper insight into understanding of CXCR4 mediated signalling pathways and its role in MM is essential to identify potential therapeutic interventions. The current therapeutic focus is on disrupting the interaction of MM cells with its protective tumor microenvironment where CXCR4 axis plays an essential role. There are still multiple challenges that need to be overcome to target CXCR4 axis more efficiently and to identify novel combination therapies with existing strategies. This review highlights the role of CXCR4 along with its significant interacting partners as a mediator of MM pathogenesis and summarizes the targeted therapies carried out so far.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jbo.2019.100253

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mesenchymal stem cells from multiple myeloma patients increase the expression of CXCL12, a chemokine essential for the homing of myeloma cells to the bone marrow, which contributes to the acceleration of disease progression.

    “Ullah et al. [32]. conducted a study indicating that MSCs from MM patients increase the expression of CXCL12, a chemokine essential for the homing of myeloma cells to the bone marrow, which contributes to the acceleration of disease progression.”

    From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as Ullah et al. [32]

    The figure caption in “Role of CXCR4 in progression of Myeloma and distant metastasis” (page unavailable) says CXCL12 expression by bone-marrow stromal cells increases after myeloma-cell adherence and promotes homing. The paper does not specify that the cells were obtained from myeloma patients or present this as a study conducted by Ullah et al.; it discusses the CXCR4/CXCL12 pathway in relation to progression rather than demonstrating that this particular increase accelerates disease progression. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 151

  1. [1]Aggarwal R. Ghobrial I.M. Roodman G.D. Chemokines in multiple myeloma Exp. Hematol. 34 10 2006 1289 1295 16982321 PMC3134145
  2. [2]Bachelerie F. Ben-Baruch A. Burkhardt A.M. Combadiere C. Farber J.M. Graham G.J. International union of basic and clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors Pharmacol. Rev. 66 1 2014 1 79 24218476 PMC3880466
  3. [3]Chen K. Bao Z. Tang P. Gong W. Yoshimura T. Wang J.M. Chemokines in homeostasis and diseases Cell Mol. Immunol. 15 4 2018 324 334 29375126 PMC6052829
  4. [4]Han X. Constitutively active chemokine CXC receptors Adv. Pharmacol. 70 2014 265 301 24931199
  5. [5]Martins-Green M. Petreaca M. Wang L. Chemokines and their receptors are key players in the orchestra that regulates wound healing Adv. Wound Care (New Rochelle) 2 7 2013 327 347 24587971 PMC3842890
  6. [6]Chatterjee S. Behnam Azad B. Nimmagadda S. The intricate role of CXCR4 in cancer Adv. Cancer Res. 124 2014 31 82 25287686 PMC4322894
  7. [7]Nazari A. Khorramdelazad H. Hassanshahi G. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer Int. J. Clin. Oncol. 22 6 2017 991 1000 29022185
  8. [8]Rossi D. Zlotnik A. The biology of chemokines and their receptors Annu. Rev. Immunol. 18 2000 217 242 10837058
  9. [9]Murphy P.M. Heusinkveld L. Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3 Cytokine 109 2018 2 10 29398278 PMC6003845
  10. [10]Kucia M. Jankowski K. Reca R. Wysoczynski M. Bandura L. Allendorf D.J. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion J. Mol. Histol. 35 3 2004 233 245 15339043
  11. [11]Busillo J.M. Armando S. Sengupta R. Meucci O. Bouvier M. Benovic J.L. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling J. Biol. Chem. 285 10 2010 7805 7817 20048153 PMC2844224
  12. [12]Xu C. Zhao H. Chen H. Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting Drug Des. Devel Ther. 9 2015 4953 4964 PMC4560524 26356032
  13. [13]Wurth R. Bajetto A. Harrison J.K. Barbieri F. Florio T. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment Front Cell Neurosci. 8 2014 144 24904289 PMC4036438
  14. [14]Fernandis A.Z. Prasad A. Band H. Klosel R. Ganju R.K. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells Oncogene 23 1 2004 157 167 14712221
  15. [15]Vila-Coro A.J. Rodriguez-Frade J.M. Martin De Ana A. Moreno-Ortiz M.C. Martinez A.C. Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway Faseb. J. 13 13 1999 1699 1710 10506573
  16. [16]Soldevila G. Licona I. Salgado A. Ramirez M. Chavez R. Garcia-Zepeda E. Impaired chemokine-induced migration during T-cell development in the absence of JAK 3 Immunology 112 2 2004 191 200 15147562 PMC1782482
  17. [17]Meng Y.M. Liang J. Wu C. Xu J. Zeng D.N. Yu X.J. Monocytes/Macrophages promote vascular CXCR4 expression via the ERK pathway in hepatocellular carcinoma Oncoimmunology 7 3 2018 e1408745 PMC5790393 29399411
  18. [18]Wang J. Cai J. Han F. Yang C. Tong Q. Cao T. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical WNT signaling pathway Int. J. Gynecol. Cancer 21 6 2011 981 987 21738044
  19. [19]Fareh M. Turchi L. Virolle V. Debruyne D. Almairac F. de-la-Forest Divonne S. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network Cell Death Differ. 19 2 2012 232 244 21720384 PMC3263498
  20. [20]Jin Z. Zhao C. Han X. Han Y. Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression BMC Cancer 12 2012 480 23075330 PMC3517772
  21. [21]Teixido J. Martinez-Moreno M. Diaz-Martinez M. Sevilla-Movilla S. The good and bad faces of the CXCR4 chemokine receptor Int. J. Biochem. Cell Biol. 95 2018 121 131 29288743
  22. [22]Meng X. Wuyi L. Yuhong X. Xinming C. Expression of CXCR4 in oral squamous cell carcinoma: correlations with clinicopathology and pivotal role of proliferation J. Oral Pathol. Med. 39 1 2010 63 68 19570110
  23. [23]Kodama J. Hasengaowa K.T. Seki N. Matsuo T. Ojima Y. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer Ann. Oncol. 18 1 2007 70 76 17032700
  24. [24]Han M. Lv S. Zhang Y. Yi R. Huang B. Fu H. The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis Tumour Biol. 35 5 2014 4589 4597 24464926
  25. [25]Lv S. Yang Y. Kwon S. Han M. Zhao F. Kang H. The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis Histopathology 64 5 2014 701 712 24422942
  26. [26]Ghanem I. Riveiro M.E. Paradis V. Faivre S. de Parga P.M. Raymond E. Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis Am. J. Transl. Res. 6 4 2014 340 352 25075251 PMC4113496
  27. [27]Liang J.J. Zhu S. Bruggeman R. Zaino R.J. Evans D.B. Fleming J.B. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma Cancer Epidemiol. Biomarkers Prev. 19 10 2010 2598 2604 20732965
  28. [28]Werner T.A. Forster C.M. Dizdar L. Verde P.E. Raba K. Schott M. CXCR4/CXCR7/CXCL12-axis in follicular thyroid carcinoma J. Cancer 9 6 2018 929 940 29581772 PMC5868160
  29. [29]Obermajer N. Muthuswamy R. Odunsi K. Edwards R.P. Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment Cancer Res. 71 24 2011 7463 7470 22025564 PMC4993027
  30. [30]Yu Y. Shi X. Shu Z. Xie T. Huang K. Wei L. Stromal cell-derived factor-1 (SDF-1)/CXCR4 axis enhances cellular invasion in ovarian carcinoma cells via integrin beta1 and beta3 expressions Oncol. Res. 21 4 2013 217 225 24762228
  31. [31]Hirata H. Hinoda Y. Kikuno N. Kawamoto K. Dahiya A.V. Suehiro Y. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility Clin. Cancer Res. 13 17 2007 5056 5062 17785557
  32. [32]Gangadhar T. Nandi S. Salgia R. The role of chemokine receptor CXCR4 in lung cancer Cancer Biol. Ther. 9 6 2010 409 416 20147779 PMC6047303
  33. [33]Corro C. Moch H. Biomarker discovery for renal cancer stem cells J. Pathol. Clin. Res. 4 1 2018 3 18 29416873 PMC5783955
  34. [34]Pan J. Mestas J. Burdick M.D. Phillips R.J. Thomas G.V. Reckamp K. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis Mol. Cancer 5 2006 56 17083723 PMC1636662
  35. [35]Liu F. Lang R. Wei J. Fan Y. Cui L. Gu F. Increased expression of SDF-1/CXCR4 is associated with lymph node metastasis of invasive micropapillary carcinoma of the breast Histopathology 54 6 2009 741 750 19438749
  36. [36]Moosavi S.R. Khorramdelazad H. Amin M. Fatahpoor S. Moogooei M. Karimabad M.N. The SDF-1 3′A genetic variation is correlated with elevated intra-tumor tissue and circulating concentration of CXCL12 in glial tumors: a study on Iranian anaplastic astrocytoma and glioblastoma multiforme patients J. Mol. Neurosci. 50 2 2013 298 304 23335032
  37. [37]Ping Y.F. Yao X.H. Chen J.H. Liu H. Chen D.L. Zhou X.D. The anti-cancer compound nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells J. Neurooncol. 84 1 2007 21 29 17415525
  38. [38]Scala S. Ottaiano A. Ascierto P.A. Cavalli M. Simeone E. Giuliano P. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma Clin. Cancer Res. 11 5 2005 1835 1841 15756007
  39. [39]Konoplev S. Rassidakis G.Z. Estey E. Kantarjian H. Liakou C.I. Huang X. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype Cancer 109 6 2007 1152 1156 17315232
  40. [40]Guo F. Wang Y. Liu J. Mok S.C. Xue F. Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks Oncogene 35 7 2016 816 826 25961926
  41. [41]Espinoza-Sanchez N.A. Enciso J. Pelayo R. Fuentes-Panana E.M. An NFkappaB-dependent mechanism of tumor cell plasticity and lateral transmission of aggressive features Oncotarget 9 42 2018 26679 26700 29928478 PMC6003573
  42. [42]Domanska U.M. Kruizinga R.C. Nagengast W.B. Timmer-Bosscha H. Huls G. de Vries E.G. A review on CXCR4/CXCL12 axis in oncology: no place to hide Eur. J. Cancer 49 1 2013 219 230 22683307
  43. [43]Cojoc M. Peitzsch C. Trautmann F. Polishchuk L. Telegeev G.D. Dubrovska A. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis Oncol. Targets Ther. 6 2013 1347 1361 PMC3794844 24124379
  44. [44]Mammadova-Bach E. Rupp T. Spenle C. Jivkov I. Shankaranarayanan P. Klein A. Laminin alpha1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma Biol. Cell 2018 29907957
  45. [45]Scarlett K.A. White E.Z. Coke C.J. Carter J.R. Bryant L.K. Hinton C.V. Agonist-induced CXCR4 and CB2 heterodimerization inhibits Galpha13/rhoa-mediated migration Mol. Cancer Res. 16 4 2018 728 739 29330286 PMC5882517
  46. [46]Kucia M. Reca R. Miekus K. Wanzeck J. Wojakowski W. Janowska-Wieczorek A. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis Stem Cells 23 7 2005 879 894 15888687
  47. [47]Furusato B. Mohamed A. Uhlen M. Rhim J.S. CXCR4 and cancer Pathol. Int. 60 7 2010 497 505 20594270
  48. [48]Zhang J. Liu C. Mo X. Shi H. Li S. Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer Oncol. Lett. 15 2 2018 1771 1776 29434873 PMC5777106
  49. [49]Guo M. Cai C. Zhao G. Qiu X. Zhao H. Ma Q. Hypoxia promotes migration and induces CXCR4 expression via HIF-1alpha activation in human osteosarcoma PLoS One 9 3 2014 e90518 24618817 PMC3949690
  50. [50]Oh Y.S. Kim H.Y. Song I.C. Yun H.J. Jo D.Y. Kim S. Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1alpha Oncol. Rep. 28 6 2012 2239 2246 23023480
  51. [51]Phillips R.J. Mestas J. Gharaee-Kermani M. Burdick M.D. Sica A. Belperio J.A. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha J. Biol. Chem. 280 23 2005 22473 22481 15802268
  52. [52]Zhao X.P. Huang Y.Y. Huang Y. Lei P. Peng J.L. Wu S. Transforming growth factor-beta1 upregulates the expression of CXC chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells Acta Pharmacol. Sin. 31 3 2010 347 354 20154716 PMC4002409
  53. [53]Gatti M. Pattarozzi A. Bajetto A. Wurth R. Daga A. Fiaschi P. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity Toxicology 314 2–3 2013 209 220 24157575
  54. [54]Kim C.G. Lee H. Gupta N. Ramachandran S. Kaushik I. Srivastava S. Role of Forkhead Box Class O proteins in cancer progression and metastasis Semin. Cancer Biol. 50 2018 142 151 28774834 PMC5794649
  55. [55]Zeng Y. Wang X. Yin B. Xia G. Shen Z. Gu W. Role of the stromal cell derived factor-1/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism J. Thorac. Dis. 9 12 2017 4947 4959 29312699 PMC5757066
  56. [56]English E.J. Mahn S.A. Marchese A. Endocytosis is required for CXC chemokine receptor type 4 (CXCR4)-mediated AKT activation and antiapoptotic signaling J. Biol. Chem. 293 29 2018 11470 11480 29899118 PMC6065176
  57. [57]Liang Z. Bian X. Shim H. Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression Breast Cancer Res. Treat. 146 3 2014 535 542 25030358
  58. [58]Shen P.F. Chen X.Q. Liao Y.C. Chen N. Zhou Q. Wei Q. MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer Prostate 74 7 2014 756 767 24644030
  59. [59]Wang Y. Yan L. Zhang L. Xu H. Chen T. Li Y. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR1553p and miR155-5p via the CXCR4 pathway in breast cancer Int. J. Oncol. 2018 PMC6065429 30015868
  60. [60]Zhu G. Liu X. Su Y. Kong F. Hong X. Lin Z. Knockdown of urothelial carcinoma associated 1 suppressed cell growth and migration through regulating miR-301a and CXCR4 in osteosarcoma MHCC97 cells Oncol. Res. 2018 PMC7848290 29523218
  61. [61]Willenbacher W. Seeber A. Steiner N. Willenbacher E. Gatalica Z. Swensen J. Towards molecular profiling in multiple myeloma: a literature review and early indications of its efficacy for informing treatment strategies Int. J. Mol. Sci. 19 7 2018 PMC6073692 30021955
  62. [62]Peled A. Klein S. Beider K. Burger J.A. Abraham M. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies Cytokine 109 2018 11 16 29903571
  63. [63]Anderson K.C. Carrasco R.D. Pathogenesis of myeloma Annu Rev Pathol 6 2011 249 274 21261519
  64. [64]Manier S. Sacco A. Leleu X. Ghobrial I.M. Roccaro A.M. Bone marrow microenvironment in multiple myeloma progression J. Biomed. Biotechnol. 2012 2012 157496 PMC3471001 23093834
  65. [65]Coniglio S.J. Role of tumor-derived chemokines in osteolytic bone metastasis Front Endocrinol. (Lausanne) 9 2018 313 29930538 PMC5999726
  66. [66]Alsayed Y. Ngo H. Runnels J. Leleu X. Singha U.K. Pitsillides C.M. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma Blood 109 7 2007 2708 2717 17119115 PMC1852222
  67. [67]Paiva B. Corchete L.A. Vidriales M.B. Puig N. Maiso P. Rodriguez I. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance Blood 127 15 2016 1896 1906 26755711
  68. [69]Azab A.K. Hu J. Quang P. Azab F. Pitsillides C. Awwad R. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features Blood 119 24 2012 5782 5794 22394600 PMC3382938
  69. [70]Kim S.W. Kim H.Y. Lee H.J. Yun H.J. Kim S. Jo D.Y. Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells Leuk. Lymphoma 50 7 2009 1163 1173 19391039
  70. [72]Vandyke K. Zeissig M.N. Hewett D.R. Martin S.K. Mrozik K.M. Cheong C.M. HIF-2alpha promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1 Cancer Res. 77 20 2017 5452 5463 28855206
  71. [73]Klasen C. Ohl K. Sternkopf M. Shachar I. Schmitz C. Heussen N. MIF promotes b cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling J. Immunol. 192 11 2014 5273 5284 24760155
  72. [74]Rajasekaran D. Groning S. Schmitz C. Zierow S. Drucker N. Bakou M. Macrophage migration inhibitory factor-CXCR4 receptor Interactions: evidence for partial allosteric agonism in comparison with CXCL12 chemokine J. Biol. Chem. 291 30 2016 15881 15895 27226569 PMC4957068
  73. [75]Zheng Y. Wang Q. Li T. Qian J. Lu Y. Li Y. Role of myeloma-derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response J. Natl. Cancer Inst. 108 11 2016 PMC5241902 27381622
  74. [76]Conley-LaComb M.K. Semaan L. Singareddy R. Li Y. Heath E.I. Kim S. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis Mol. Cancer 15 1 2016 68 27809841 PMC5093938
  75. [77]Balabanian K. Lagane B. Infantino S. Chow K.Y. Harriague J. Moepps B. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes J. Biol. Chem. 280 42 2005 35760 35766 16107333
  76. [78]Azab A.K. Sahin I. Moschetta M. Mishima Y. Burwick N. Zimmermann J. CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma Blood 124 12 2014 1905 1914 25079359 PMC4168345
  77. [79]Kometani K. Kurosaki T. Differentiation and maintenance of long-lived plasma cells Curr. Opin. Immunol. 33 2015 64 69 25677584
  78. [80]Waldschmidt J.M. Simon A. Wider D. Muller S.J. Follo M. Ihorst G. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma Br. J. Haematol. 179 1 2017 36 49 28670693
  79. [81]Hideshima T. Chauhan D. Hayashi T. Podar K. Akiyama M. Gupta D. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma Mol. Cancer Ther. 1 7 2002 539 544 12479272
  80. [82]Parmo-Cabanas M. Bartolome R.A. Wright N. Hidalgo A. Drager A.M. Teixido J. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion Exp. Cell Res. 294 2 2004 571 580 15023543
  81. [83]Follin-Arbelet V. Hofgaard P.O. Hauglin H. Naderi S. Sundan A. Blomhoff R. Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model BMC Cancer 11 2011 301 21767374 PMC3161033
  82. [84]Jung O. Trapp-Stamborski V. Purushothaman A. Jin H. Wang H. Sanderson R.D. Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins Oncogenesis 5 2016 e202 26926788 PMC5154350
  83. [85]Colombo M. Galletti S. Garavelli S. Platonova N. Paoli A. Basile A. Notch signaling deregulation in multiple myeloma: a rational molecular target Oncotarget 6 29 2015 26826 26840 26308486 PMC4694956
  84. [86]Hirbe A.C. Rubin J. Uluckan O. Morgan E.A. Eagleton M.C. Prior J.L. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone Proc. Natl. Acad. Sci. USA 104 35 2007 14062 14067 17715292 PMC1955795
  85. [87]Yaccoby S. Two states of myeloma stem cells Clin. Lymph. Myeloma. Leuk. 18 1 2018 38 43 29066162
  86. [88]Terpos E. Ntanasis-Stathopoulos I. Gavriatopoulou M. Dimopoulos M.A. Pathogenesis of bone disease in multiple myeloma: from bench to bedside Blood Cancer J. 8 1 2018 7 29330358 PMC5802524
  87. [89]Samant S. Role of osteopontin in the pathophysiology of cancer Matrix Biol. 37 2014 131 141 24657887 PMC5916777
  88. [91]Ooi L.L. Dunstan C.R. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma J. Bone Miner Res. 24 7 2009 1147 1149 19419311
  89. [92]Marchica V. Accardi F. Storti P. Mancini C. Martella E. Dalla Palma B. Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? Int. J. Hematol. 105 1 2016 104 108 27699576
  90. [93]Langley R.R. Fidler I.J. The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs Int. J. Cancer 128 11 2011 2527 2535 21365651 PMC3075088
  91. [94]Ghobrial I.M. Myeloma as a model for the process of metastasis: implications for therapy Blood 120 1 2012 20 30 22535658 PMC3390959
  92. [95]Roccaro A.M. Mishima Y. Sacco A. Moschetta M. Tai Y.T. Shi J. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation Cell Rep. 12 4 2015 622 635 26190113 PMC4961259
  93. [96]Azab A.K. Quang P. Azab F. Pitsillides C. Thompson B. Chonghaile T. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment Blood 119 6 2012 1468 1478 22096244 PMC3286211
  94. [97]Sisay M. Mengistu G. Edessa D. The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy Onco. Targets Ther. 10 2017 3801 3810 28794644 PMC5538694
  95. [98]Zdzisinska B. Kandefer-Szerszen M. The role of RANK/RANKL and OPG in multiple myeloma Postepy Hig. Med. Dosw. (Online) 60 2006 471 482 17013366
  96. [99]Benslimane-Ahmim Z. Pereira J. Lokajczyk A. Dizier B. Galy-Fauroux I. Fischer A.M. Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization Cancer Lett. 395 2017 11 19 28263839
  97. [100]Reisenbuckler C. Multiple myeloma and diagnostic imaging Radiol. Technol. 85 4 2014 391 410 quiz 1-3 24614435
  98. [101]Gomis R.R. Gawrzak S. Tumor cell dormancy Mol. Oncol. 2016 PMC5423221 28017284
  99. [102]Kikuchi J. Kuroda Y. Koyama D. Osada N. Izumi T. Yasui H. Myeloma cells are activated in bone marrow microenvironment by the CD180/MD-1 complex, which senses lipopolysaccharide Cancer Res. 78 7 2018 1766 1778 29363546
  100. [103]Lawson M.A. McDonald M.M. Kovacic N. Hua Khoo W. Terry R.L. Down J. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche Nat. Commun. 6 2015 8983 26632274 PMC4686867
  101. [104]Gelmini S. Mangoni M. Serio M. Romagnani P. Lazzeri E. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis J. Endocrinol. Invest. 31 9 2008 809 819 18997494
  102. [105]Blade J. Fernandez de Larrea C. Rosinol L. Extramedullary disease in multiple myeloma in the era of novel agents Br. J. Haematol. 169 6 2015 763 765 25825255
  103. [106]Stessman H.A. Mansoor A. Zhan F. Janz S. Linden M.A. Baughn L.B. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib Leukemia 27 10 2013 2075 2077 23728080 PMC4053943
  104. [109]Keane N.A. Reidy M. Natoni A. Raab M.S. O'Dwyer M. Targeting the PIM kinases in multiple myeloma Blood Cancer J. 5 2015 e325 26186558 PMC4526774
  105. [110]Solimando A.G. Brandl A. Mattenheimer K. Graf C. Ritz M. Ruckdeschel A. JAM-A as a prognostic factor and new therapeutic target in multiple myeloma Leukemia 32 3 2018 736 743 29064484 PMC5843918
  106. [111]Chang C.H. Hale S.J. Cox C.V. Blair A. Kronsteiner B. Grabowska R. Junctional adhesion molecule – a is highly expressed on human hematopoietic repopulating cells and associates with the key hematopoietic chemokine receptor CXCR4 Stem Cells 34 6 2016 1664 1678 26866290
  107. [112]Turner J.G. Dawson J.L. Grant S. Shain K.H. Dalton W.S. Dai Y. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors J. Hematol. Oncol. 9 1 2016 73 27557643 PMC4997728
  108. [113]Liu S.H. Gu Y. Pascual B. Yan Z. Hallin M. Zhang C. A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies Blood Adv. 1 15 2017 1088 1100 29296751 PMC5728311
  109. [116]Ro T.B. Holien T. Fagerli U.M. Hov H. Misund K. Waage A. HGF and IGF-1 synergize with SDF-1alpha in promoting migration of myeloma cells by cooperative activation of p21-activated kinase Exp. Hematol. 41 7 2013 646 655 23499762
  110. [117]Furukawa Y. Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma Int. J. Hematol. 104 3 2016 281 292 27411688
  111. [118]Tsubaki M. Takeda T. Yoshizumi M. Ueda E. Itoh T. Imano M. RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines Tumour Biol. 37 7 2016 9099 9110 26762414
  112. [119]Ryu J. Koh Y. Park H. Kim D.Y. Kim D.C. Byun J.M. Highly expressed Integrin-alpha8 induces epithelial to mesenchymal transition-like features in multiple myeloma with early relapse Mol. Cells 39 12 2016 898 908 28008160 PMC5223107
  113. [120]Di Marzo L. Desantis V. Solimando A.G. Ruggieri S. Annese T. Nico B. Microenvironment drug resistance in multiple myeloma: emerging new players Oncotarget 7 37 2016 60698 60711 27474171 PMC5312413
  114. [121]Nefedova Y. Sullivan D.M. Bolick S.C. Dalton W.S. Gabrilovich D.I. Inhibition of notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy Blood 111 4 2008 2220 2229 18039953
  115. [122]Abdi J. Chen G. Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms Oncotarget 4 12 2013 2186 2207 24327604 PMC3926819
  116. [123]Roccaro A.M. Sacco A. Purschke W.G. Moschetta M. Buchner K. Maasch C. SDF-1 inhibition targets the bone marrow niche for cancer therapy Cell Rep. 9 1 2014 118 128 25263552 PMC4194173
  117. [124]Fruehauf S. Ehninger G. Hubel K. Topaly J. Goldschmidt H. Ho A.D. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients Bone Marrow Transplant 45 2 2010 269 275 19597422
  118. [125]Fruehauf S. Seeger T. Maier P. Li L. Weinhardt S. Laufs S. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics Exp. Hematol. 34 8 2006 1052 1059 16863911
  119. [126]Fruehauf S. Veldwijk M.R. Seeger T. Schubert M. Laufs S. Topaly J. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study Cytotherapy 11 8 2009 992 1001 19929463
  120. [127]Debnath B. Xu S. Grande F. Garofalo A. Neamati N. Small molecule inhibitors of CXCR4 Theranostics 3 1 2013 47 75 23382786 PMC3563081
  121. [128]Bouyssou J.M. Ghobrial I.M. Roccaro A.M. Targeting SDF-1 in multiple myeloma tumor microenvironment Cancer Lett. 380 1 2016 315 318 26655999
  122. [129]Azab A.K. Runnels J.M. Pitsillides C. Moreau A.S. Azab F. Leleu X. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy Blood 113 18 2009 4341 4351 19139079 PMC2676090
  123. [130]Kashyap M.K. Amaya-Chanaga C.I. Kumar D. Simmons B. Huser N. Gu Y. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia J. Hematol. Oncol. 10 1 2017 112 28526063 PMC5438492
  124. [131]Peled A. Abraham M. Avivi I. Rowe J.M. Beider K. Wald H. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma Clin. Cancer Res. 20 2 2014 469 479 24246358
  125. [132]Beider K. Begin M. Abraham M. Wald H. Weiss I.D. Wald O. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth Exp. Hematol. 39 3 2011 282 292 21138752
  126. [133]Pilar de la Puente B.M. Azab F. Luderer M. Azab A.K. Molecularly targeted therapies in multiple myeloma Leuk. Res. Treatment. 2014 976567 2014 1 8 PMC4009206 24829804
  127. [134]Berenson J.R. Hilger J.D. Yellin O. Boccia R.V. Matous J. Dressler K. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma Ann. Hematol. 93 1 2014 89 98 24135804
  128. [135]Richardson P.G. Hungria V.T. Yoon S.S. Beksac M. Dimopoulos M.A. Elghandour A. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment Blood 127 6 2016 713 721 26631116 PMC4760132
  129. [136]San-Miguel J.F. Hungria V.T. Yoon S.S. Beksac M. Dimopoulos M.A. Elghandour A. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Lancet Oncol. 15 11 2014 1195 1206 25242045
  130. [137]San-Miguel J.F. Hungria V.T. Yoon S.S. Beksac M. Dimopoulos M.A. Elghandour A. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial Lancet Haematol. 3 11 2016 e506 ee15 27751707
  131. [138]Kuhne M.R. Mulvey T. Belanger B. Chen S. Pan C. Chong C. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies Clin. Cancer Res. 19 2 2013 357 366 23213054
  132. [139]Lonial S. Durie B. Palumbo A. San-Miguel J. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Leukemia 30 3 2016 526 535 26265184 PMC4777772
  133. [141]Broussas M. Boute N. Akla B. Berger S. Beau-Larvor C. Champion T. A new Anti-CXCR4 antibody that blocks the CXCR4/SDF-1 axis and mobilizes effector cells Mol. Cancer Ther. 15 8 2016 1890 1899 27297868
  134. [142]Fouquet G. Guidez S. Richez V. Stoppa A.M. Le Tourneau C. Macro M. Phase i dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma Oncotarget 9 35 2018 23890 23899 29844860 PMC5963612
  135. [143]Sheng-Bin Peng X.Z. Paul D. Kays L.M. Ye M. Vaillancourt P. Dowless M. Stancato L.F. Stewart J. Uhlik M.T. Long H. Chu S. Obungu V.H. Inhibition of CXCR4 by LY2624587, a fully humanized anti-CXCR4 antibody induces apoptosis of hematologic malignancies PLoS One 11 3 2016 e0150585 PMC4782998 26954567
  136. [144]Lapa C. Herrmann K. Schirbel A. Hanscheid H. Luckerath K. Schottelius M. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma Theranostics 7 6 2017 1589 1597 28529638 PMC5436514
  137. [145]Xue L.-J. Mao X.-B. Ren L.-L. Chu X.-Y. Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma Cancer Med. 6 6 2017 1424 1436 28544785 PMC5463074
  138. [146]Oliveira A.M. M D. Metzger M. Linardi C. Giorgi R.R. Moura F. Martinez G.A. Bydlowski S.P. Novak E.M. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients Leuk Res. 33 7 2009 970 973 18976811
  139. [147]Udi J. Schüler J. Wider D. Ihorst G. Catusse J. Waldschmidt J. Potentin vitroandin vivoactivity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization Br. J. Haematol. 161 1 2013 104 116 23384035
  140. [148]Badr G. Lefevre E.A. Mohany M. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis PLoS One 6 9 2011 e23741 21912642 PMC3164673
  141. [149]Zirafi O. Hermann P. Münch J. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4 J. Leukoc. Biol. 99 6 2016 863 868 26965637
  142. [150]Buske C. Kirchhoff F. Münch J. EPI-X4, a novel endogenous antagonist of CXCR4 Oncotarget 6 34 2015 35137 35138 26459389 PMC4742086
  143. [151]Dugan M.J. Maziarz R.T. Bensinger W.I. Nademanee A. Liesveld J. Badel K. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization Bone Marrow Transplant 45 1 2010 39 47 19483760
  144. [153]Rettig M.P. Ansstas G. DiPersio J.F. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4 Leukemia 26 1 2012 34 53 21886173 PMC3514440
  145. [154]Angelopoulou M.K. Tsirkinidis P. Boutsikas G. Vassilakopoulos T.P. Tsirigotis P. New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients Biomed. Res. Int. 2014 2014 835138 PMC4150414 25197663
  146. [155]Imai Y. Ohta E. Takeda S. Sunamura S. Ishibashi M. Tamura H. Wang Y.H. Deguchi A. Tanaka J. Maru Y. Motoji T. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma JCI Insight 21 5 2016 e85061 1 PMC5033869 27699258
  147. [156]de Nigris F. Schiano C. Infante T. Napoli C. CXCR4 inhibitors: tumor vasculature and therapeutic challenges Recent Pat. Anticancer Drug Discov. 7 3 2012 251 264 22376154
  148. [157]Zhang Y. Depond M. He L. Foudi A. Kwarteng E.O. Lauret E. CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress Sci. Rep. 6 2016 37827 27886253 PMC5122894
  149. [158]Karpova D. Bonig H. Concise Review: CXCR4/CXCL12 signaling in immature hematopoiesis–lessons from pharmacological and genetic models Stem Cells 33 8 2015 2391 2399 25966814
  150. [159]de la Puente P. Muz B. Azab F. Luderer M. Azab A.K. Molecularly targeted therapies in multiple myeloma Leuk. Res. Treatment 2014 2014 976567 PMC4009206 24829804
  151. [160]Sierro F. Biben C. Martinez-Munoz L. Mellado M. Ransohoff R.M. Li M. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 Proc. Natl. Acad. Sci. USA 104 37 2007 14759 14764 17804806 PMC1976222

Cited by

Sorted by citations

Authors
Ullah, T. R.
Affiliations
Hudson Institute of Medical Research (AU)
Corresponding author
Ullah, Tomalika Rahmat
ORCID
Ullah, Tomalika Rahmat
Venue
Journal of Bone Oncology
Publisher
Elsevier BV
Published
2019-08
Volume
17
Pages
100253
ISSN
  • 2212-1366 (ISSN-L)
  • 2212-1374
DOI
10.1016/j.jbo.2019.100253
PMC
PMC6658931
OpenAlex
W2958089272
Cited by
141
References
1
Citations by year
2026: 17 · 2025: 22 · 2024: 19 · 2023: 18 · 2022: 32 · 2021: 17 · 2020: 14 · 2019: 2
FWCI
2.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of bone oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
Keywords
CXCR4, multiple myeloma, CXCL12, chemokine signaling, bone marrow homing, metastasis, drug resistance, osteoclastogenesis, tumor microenvironment, signaling pathways, targeted therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review